Skip to main content
Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MIST ISIN · USU6005B1045 LEI · 549300P43IPGW3Q3Y026 US Manufacturing
Open in API
Filings indexed 346 across all filing types
Latest filing 2019-05-15 Major Shareholding Noti…
Country US United States of America
Listing US MIST

About Milestone Pharmaceuticals Inc.

https://www.milestonepharma.com

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. The company's lead investigational product is etripamil, a novel, fast-acting calcium channel blocker delivered as a nasal spray. This formulation is designed for patient self-administration to terminate episodes of certain heart rhythm disturbances outside of a hospital or emergency department setting. The primary indications under investigation for etripamil are paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR), aiming to address unmet needs for acute, at-home treatment of these episodic conditions.

Recent filings

Filing Released Lang Actions
SC 13G Filing
Major Shareholding Notification
2019-05-15 English
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 13, 2019, by Milestone Pharmaceuticals Inc. It reports amendments to the Articles of Incorporation and Bylaws related to the closing of the company's initial public offering (IPO). It also announces the closing of the IPO and the exercise of the underwriters' option to purchase additional shares, including gross proceeds details. The document includes press releases as exhibits and signatures from the company's Vice President, Finance. The content focuses on corporate governance changes and capital raising events, specifically the IPO closing and related amendments. This fits the category of Capital/Financing Update (CAP) because it provides updates on the company's financing activities and capital structure changes. The document is not a full financial report, earnings release, or regulatory filing of another type, but a current report on significant corporate events related to financing.
2019-05-15 English
4 Filing
Director's Dealing
2019-05-14 English
4 Filing
Director's Dealing
2019-05-14 English
SC 13D Filing
Major Shareholding Notification
2019-05-14 English
424B4 Filing
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus for an initial public offering (IPO) of common shares by Milestone Pharmaceuticals Inc. It includes sections typical of a prospectus such as risk factors, use of proceeds, dividend policy, capitalization, dilution, selected consolidated financial data, management's discussion and analysis, business overview, management, executive compensation, principal shareholders, description of share capital, underwriting, legal matters, and financial statements. The document is filed pursuant to Rule 424(b)(4), which is a SEC rule related to prospectus filings for securities offerings. This is not an annual report, earnings release, or any other financial report type but a capital markets document related to financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-05-09 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.